Chordoma – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:37:03 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Chordoma – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Effectiveness and Safety of Regorafenib for Patients with Metastatic Bone Sarcomas https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-regorafenib-for-patients-with-metastatic-bone-sarcomas/ Wed, 29 Apr 2026 15:00:51 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-regorafenib-for-patients-with-metastatic-bone-sarcomas/ This clinical trial is focused on studying the effects of a medication called regorafenib in patients with a type of cancer known as metastatic bone sarcoma. Metastatic bone sarcoma is a cancer that starts in the bones and can spread to other parts of the body. The purpose of the study is to evaluate how well regorafenib works in treating this condition and to assess its safety for patients.

Participants in the study will receive either regorafenib or a placebo, which is a substance with no active medication. The study will take place over several months, during which patients will be monitored regularly to see how their cancer responds to the treatment. This will involve various assessments, including imaging tests like MRI or CT scans, to track changes in the cancer. The study aims to determine if regorafenib can help control the cancer and improve the patients’ quality of life.

Throughout the study, patients will be closely observed for any side effects or changes in their condition. The information gathered will help researchers understand the potential benefits and risks of using regorafenib for treating metastatic bone sarcoma. This research is important for developing new treatment options for patients with this challenging type of cancer.

]]>